Cargando…
Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS
BACKGROUND: While immediate benefits of levodopa–carbidopa intestinal gel (LCIG) are evident in patients with Parkinson’s disease (PD), long-term LCIG effects require further study. OBJECTIVES: We explored long-term LCIG on motor symptoms, nonmotor symptoms (NMS), and LCIG treatment settings in pati...
Autores principales: | Fasano, Alfonso, García-Ramos, Rocío, Gurevich, Tanya, Jech, Robert, Bergmann, Lars, Sanchez-Soliño, Olga, Parra, Juan Carlos, Simu, Mihaela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130122/ https://www.ncbi.nlm.nih.gov/pubmed/36802031 http://dx.doi.org/10.1007/s00415-023-11615-3 |
Ejemplares similares
-
Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study
por: Fasano, Alfonso, et al.
Publicado: (2021) -
Advanced Parkinson’s Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis
por: Simu, Mihaela Adriana, et al.
Publicado: (2021) -
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
por: Chaudhuri, K. Ray, et al.
Publicado: (2023) -
Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial
por: Freire‐Alvarez, Eric, et al.
Publicado: (2021) -
Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel
por: Kovács, Norbert, et al.
Publicado: (2022)